French Observatory of Familial Hypercholesterolemia in Cardiology

NCT02013713 | Terminated

• 1 other identifier: 12 449
• Study Type: observational
• Target: 31
• Locations: 1 country
• Sites: 1

Brief Summary

The Family Hypercholesterolemia remains poorly diagnosed disease with an outlet sometimes suboptimal care. However, the Family Hypercholesterolemia exposes patients concerned at increased cardiovascular risk. The frequency of familial hypercholesterolemia in cardiologic is little studied and remains unknown, and there is little data on the profile of patients, diagnostic methods and management. Main objectives:

• Establish a monitoring patients with hypercholesterolemia Family cardiology in France
• Characterize the Family hypercholesterolemia in cardiology, including assessing the frequency of the most severe forms, which are at higher cardiovascular risk.

Conditions

Familial Hypercholesterolemia

Keywords

Cardiology; Family Hypercholesterolemia

Outcome Measures

Primary Outcomes (1)

• Frequency of the Family Hypercholesterolemia in cardiology

  Number of Family Hypercholesterolemia among patients with LDL-C\> 1.9g / l without hypoglycemic treatment or\> 1.6g / l in lipid-lowering therapy

  1 day

Study Arms (1)

Family Hypercholesterolemia in cardiology

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study is proposed to cardiology services hospitals. Aged 18 or more, seen in cardiology (USIC, Hospitalization, Consultation), who agreed to participate in the observatory, and coronary patients who have LDL-c levels

You may qualify if:

• coronary patients
• who agreed to participate
• high LDL-c levels: \* LDL-c\> = 1.9g / l without lipid lowering treatment according to the diagnostic score of Family Hypercholesterolemia these coronary patients with LDL\> 1.9g / l may possibly or probably be achieved Hypercholesterolemia Family.
• \* LDL-c\> = 1.6g / l in lipid-lowering treatment, the reduction of LDL-c average expected under standard lipid-lowering therapy (statin alone) being 30-40% of these patients had therefore pretreatment levels greater than 2 g / l or greater than 2.5 g / l and may possibly or probably be achieved Family Hypercholesterolemia after the diagnostic score.

You may not qualify if:

• Expressed refusal to participate in the observatory
• Age ≤ 18

Sponsors & Collaborators

• French Cardiology Society: lead

Study Sites (1)

European Hospital Georges Pompidou

Paris, 75015, France

Location

Related Publications (1)

• Civeira F; International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004 Mar;173(1):55-68. doi: 10.1016/j.atherosclerosis.2003.11.010.

  PMID: 15177124 BACKGROUND

MeSH Terms

Conditions

Hyperlipoproteinemia Type II

Condition Hierarchy (Ancestors)

Lipid Metabolism, Inborn Errors; Metabolism, Inborn Errors; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Hyperlipoproteinemias; Hyperlipidemias; Dyslipidemias; Lipid Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 6, 2013
• First Posted: December 17, 2013
• Study Start: November 1, 2014
• Primary Completion: December 1, 2016
• Study Completion: December 1, 2016
• Last Updated: August 7, 2019

Record last verified: 2019-08

Locations

FR (1)